Two Cases of Viral Re-suppression After M184V + R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification
Authors:
- 9 January 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 79 (1) , 198-201
Abstract
Dolutegravir/lamivudine (DTG/3TC) has a high genetic barrier against the development of human immunodeficiency virus drug resistance. We report 2 cases of R263K + M184V mutations during DTG/3TC failure followed by viral suppression after adherence intervention without treatment change that we attribute to residual drug activity, reduced viral fitness, and robust immune competence.Keywords
This publication has 12 references indexed in Scilit:
- The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and IntegrationAntimicrobial Agents and Chemotherapy, 2023
- Three‐year efficacy of switching to dolutegravir plus lamivudine: A real‐world studyHIV Medicine, 2023
- Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppressionJournal of Antimicrobial Chemotherapy, 2022
- Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled TrialsOpen Forum Infectious Diseases, 2022
- Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infectionAIDS, 2021
- Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE TrialClinical Infectious Diseases, 2021
- Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravirJournal of Antimicrobial Chemotherapy, 2020
- ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)–infected Participants With HIV-1 RNA <500000 Copies/mLClinical Infectious Diseases, 2017
- Combination of the R263K and M184I/V Resistance Substitutions against Dolutegravir and Lamivudine Decreases HIV Replicative CapacityAntimicrobial Agents and Chemotherapy, 2015
- Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adultsAIDS, 2011